Previous research has suggested that fucoidan may act as a therapeutic agent in breast cancer through a ubiquitin-dependent degradation pathway affecting the TGFR/Smad/Snail, Slug, Twist and epithelial-mesenchymal transition axes (Hsu et al., 2013). Here, SNAI2 is linked to breast carcinoma.